MEMBER'S LOGINX

Remember Username
Keep me signed in

(Please do not use this option on a public machine)

Home
Research It
Compare Company
International - miscellaneous
DR. DATSONS LABS - ACTAVIS (US)

DR. DATSONS LABS vs ACTAVIS (US) - Comparison Results

Mail
Print
FaceBook
Twitter
Linked In
WhatsApp

ACTAVIS (US)
Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

DR. DATSONS LABS

ACTAVIS

EQUITY SHARE DATA
		DR. DATSONS LABS Mar-14	ACTAVIS Dec-18	DR. DATSONS LABS/ ACTAVIS	5-Yr Chart Click to enlarge
High	Rs	126	14,315	-
Low	Rs	31	9,603	-
Sales per share (Unadj.)	Rs	133.0	3,511.5	-
Earnings per share (Unadj.)	Rs	0.2	-1,131.1	-
Cash flow per share (Unadj.)	Rs	6.6	370.0	-
Dividends per share (Unadj.)	Rs	0	0	-
Dividend yield (eoy)	%	0	0	-
Book value per share (Unadj.)	Rs	128.8	14,483.3	-
Shares outstanding (eoy)	m	31.66	332.60	-
Bonus/Rights/Conversions		FCCB	-	-
Price / Sales ratio	x	0.6	3.4	17.3%
Avg P/E ratio	x	516.1	-10.6	-4,881.4%
P/CF ratio (eoy)	x	11.8	32.3	36.6%
Price / Book Value ratio	x	0.6	0.8	73.6%
Dividend payout	%	0	0	-
Avg Mkt Cap	Rs m	2,477	3,977,519	0.1%
No. of employees	`000	NA	16.9	0.0%
Total wages/salary	Rs m	56	0	-
Avg. sales/employee	Rs Th	NM	69,107.8	-
Avg. wages/employee	Rs Th	NM	0	-
Avg. net profit/employee	Rs Th	NM	-22,259.7	-

INCOME DATA
Net Sales	Rs m	4,211	1,167,922	0.4%
Other income	Rs m	79	22,335	0.4%
Total revenues	Rs m	4,289	1,190,257	0.4%
Gross profit	Rs m	569	30,606	1.9%
Depreciation	Rs m	204	499,261	0.0%
Interest	Rs m	430	67,396	0.6%
Profit before tax	Rs m	13	-513,717	-0.0%
Minority Interest	Rs m	0	0	-
Prior Period Items	Rs m	-2	0	-
Extraordinary Inc (Exp)	Rs m	0	131,019	0.0%
Tax	Rs m	6	-6,510	-0.1%
Profit after tax	Rs m	5	-376,188	-0.0%
Gross profit margin	%	13.5	2.6	515.3%
Effective tax rate	%	48.0	1.3	3,790.1%
Net profit margin	%	0.1	-32.2	-0.4%

BALANCE SHEET DATA
Current assets	Rs m	6,852	479,021	1.4%
Current liabilities	Rs m	6,711	423,757	1.6%
Net working cap to sales	%	3.3	4.7	70.8%
Current ratio	x	1.0	1.1	90.3%
Inventory Days	Days	161	20	821.3%
Debtors Days	Days	318	66	480.3%
Net fixed assets	Rs m	3,673	132,202	2.8%
Share capital	Rs m	317	0	-
"Free" reserves	Rs m	3,761	0	-
Net worth	Rs m	4,078	4,817,134	0.1%
Long term debt	Rs m	1,671	1,696,287	0.1%
Total assets	Rs m	12,633	7,530,276	0.2%
Interest coverage	x	1.0	-6.6	-15.5%
Debt to equity ratio	x	0.4	0.4	116.4%
Sales to assets ratio	x	0.3	0.2	214.9%
Return on assets	%	3.4	-4.1	-84.0%
Return on equity	%	0.1	-7.8	-1.5%
Return on capital	%	7.7	-4.8	-158.5%
Exports to sales	%	22.9	0	-
Imports to sales	%	14.3	0	-
Net fx	Rs m	357	0	-

CASH FLOW
From Operations	Rs m	1,345	417,255	0.3%
From Investments	Rs m	-2,256	229,227	-1.0%
From Financial Activity	Rs m	-1,200	-716,134	0.2%
Net Cashflow	Rs m	-2,111	-69,304	3.0%

NM: Not Meaningful

Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.98 Rs / USD

Compare DR. DATSONS LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)

Compare DR. DATSONS LABS With: ELDER PHARMA ALEMBIC PHARMA UNICHEM LAB CIPLA GSK PHARMA

Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.